Callan Family Office LLC Buys Shares of 16,418 Royalty Pharma PLC $RPRX

Key Points

• Callan Family Office LLC acquired 16,418 shares of Royalty Pharma PLC, valued at approximately $592,000, during the second quarter.
• Royalty Pharma reported an earnings per share (EPS) of $1.14 for the last quarter, exceeding analyst estimates of $1.10, but had a revenue of $578.67 million which was below the expected $750.06 million.
• The company recently announced a quarterly dividend of $0.22 per share, representing an annualized dividend yield of 2.5%.

Callan Family Office LLC bought a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 16,418 shares of the biopharmaceutical company's stock, valued at approximately $592,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. M&T Bank Corp grew its stake in Royalty Pharma by 23.4% during the 1st quarter. M&T Bank Corp now owns 28,967 shares of the biopharmaceutical company's stock valued at $902,000 after acquiring an additional 5,500 shares in the last quarter. Yousif Capital Management LLC purchased a new position in Royalty Pharma during the 1st quarter valued at about $275,000. Asset Management One Co. Ltd. grew its stake in Royalty Pharma by 8.0% during the 1st quarter. Asset Management One Co. Ltd. now owns 164,931 shares of the biopharmaceutical company's stock valued at $5,134,000 after acquiring an additional 12,148 shares in the last quarter. Amalgamated Bank grew its stake in Royalty Pharma by 4.4% during the 1st quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company's stock valued at $636,000 after acquiring an additional 866 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Royalty Pharma in the 1st quarter valued at approximately $1,665,000. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Down 1.6%

Shares of Royalty Pharma stock opened at $35.44 on Tuesday. The stock has a market capitalization of $20.67 billion, a P/E ratio of 20.49, a PEG ratio of 1.98 and a beta of 0.60. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74. The stock has a 50 day moving average price of $36.13 and a two-hundred day moving average price of $34.70. Royalty Pharma PLC has a 12-month low of $24.05 and a 12-month high of $38.00.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The firm had revenue of $578.67 million during the quarter, compared to analysts' expectations of $750.06 million. Equities analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, August 15th. Royalty Pharma's dividend payout ratio is currently 50.87%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on RPRX. Morgan Stanley dropped their price objective on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating on the stock in a report on Friday. Citigroup increased their price objective on Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, July 22nd. Weiss Ratings upgraded Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Wall Street Zen downgraded Royalty Pharma from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Finally, The Goldman Sachs Group began coverage on Royalty Pharma in a report on Tuesday, September 30th. They issued a "buy" rating and a $42.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $46.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.